{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T14:15:05Z","timestamp":1782137705608,"version":"3.54.5"},"reference-count":29,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,11,13]],"date-time":"2015-11-13T00:00:00Z","timestamp":1447372800000},"content-version":"vor","delay-in-days":650,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1097\/jto.0000000000000051","type":"journal-article","created":{"date-parts":[[2014,1,14]],"date-time":"2014-01-14T04:34:05Z","timestamp":1389674045000},"page":"231-238","source":"Crossref","is-referenced-by-count":56,"title":["Prospective Study on the Incidence of Bone Metastasis (BM) and Skeletal-Related Events (SREs) in Patients (pts) with Stage IIIB and IV Lung Cancer\u2014CSP-HOR 13"],"prefix":"10.1016","volume":"9","author":[{"given":"Nobuyuki","family":"Katakami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kunikane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Takayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Sawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soichiro","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isao","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Eguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1097\/JTO.0000000000000051_bib1","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/nrc867","article-title":"Metastasis to bone: causes, consequences and therapeutic opportunities","volume":"2","author":"Mundy","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"10.1097\/JTO.0000000000000051_bib2","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","article-title":"Metastatic bone disease: clinical features, pathophysiology and treatment strategies","volume":"27","author":"Coleman","year":"2001","journal-title":"Cancer Treat Rev"},{"key":"10.1097\/JTO.0000000000000051_bib3","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1056\/NEJMoa011954","article-title":"Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer","volume":"346","author":"Schiller","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1097\/JTO.0000000000000051_bib4","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1093\/annonc\/mdl377","article-title":"Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: four-Arm Cooperative Study in Japan","volume":"18","author":"Ohe","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1097\/JTO.0000000000000051_bib5","first-page":"7507","volume":"30","author":"Paz-Ares","year":"2012","journal-title":"ASCO Meeting Abstracts"},{"key":"10.1097\/JTO.0000000000000051_bib6","first-page":"7515","article-title":"Randomized phase III trial of S-1 plus cisplatin versus docetaxel plus cisplatin for advanced non-small-cell Lung cancer (TCOG0701)\u2014CATS TRIAL (cisplatin and TS-1 TRIAL)","volume":"30","author":"Katakami","year":"2012","journal-title":"ASCO Meeting Abstracts"},{"issue":"Suppl 8","key":"10.1097\/JTO.0000000000000051_bib7","first-page":"LBA 2","article-title":"Final overall survival (OS) results from a phase III, randomised, open-label, first-line study of gefitinib (G) v carboplatin\/paclitaxel (C\/P) in clinically selected patients with advanced nonsmall cell lung cancer (NSCL) in Asia (IPASS)","volume":"21","author":"Yang","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1097\/JTO.0000000000000051_bib8","first-page":"7519","article-title":"Final overall survival results of NEJ002, a phase III trial comparing gefitinib to carboplatin (CBDCA) plus paclitaxel (TXL) as the first-line treatment for advanced non-small cell lung cancer (NSCLC) with EGFR mutations","volume":"29","author":"Inoue","year":"2011","journal-title":"ASCO Meeting Abstracts"},{"key":"10.1097\/JTO.0000000000000051_bib9","first-page":"7521","volume":"30","author":"Mitsudomi","year":"2012","journal-title":"ASCO Meeting Abstracts"},{"key":"10.1097\/JTO.0000000000000051_bib10","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1056\/NEJMoa003034","article-title":"Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer","volume":"346","author":"Noda","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1097\/JTO.0000000000000051_bib11","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1200\/JCO.2005.04.8595","article-title":"Randomized phase III trial comparing irinotecan\/cisplatin with etoposide\/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer","volume":"24","author":"Hanna","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0000000000000051_bib12","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1056\/NEJM199901283400403","article-title":"Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide","volume":"340","author":"Turrisi","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1097\/JTO.0000000000000051_bib13","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.1200\/JCO.2002.12.071","article-title":"Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104","volume":"20","author":"Takada","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0000000000000051_bib14","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1056\/NEJM199612123352401","article-title":"Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group","volume":"335","author":"Hortobagyi","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1097\/JTO.0000000000000051_bib15","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2003.04.105","article-title":"Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial\u2014the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group","volume":"21","author":"Rosen","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0000000000000051_bib16","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0000000000000051_bib17","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/CCO.0b013e3282f54cf2","article-title":"The changing landscape of the medical management of skeletal metastases in nonsmall cell lung cancer","volume":"20","author":"Kosteva","year":"2008","journal-title":"Curr Opin Oncol"},{"issue":"Suppl 1","key":"10.1097\/JTO.0000000000000051_bib18","first-page":"S45","article-title":"Incidence and distribution of skeletal metastases in NSCLC in the era of PET [abstract]","volume":"46","author":"Kosteva","year":"2004","journal-title":"Lung Cancer"},{"key":"10.1097\/JTO.0000000000000051_bib19","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.lungcan.2007.03.013","article-title":"Skeletal metastases in non-small cell lung cancer: a retrospective study","volume":"57","author":"Tsuya","year":"2007","journal-title":"Lung Cancer"},{"key":"10.1097\/JTO.0000000000000051_bib20","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s002590100474","article-title":"FDG-PET imaging for the staging and follow-up of small cell lung cancer","volume":"28","author":"Schumacher","year":"2001","journal-title":"Eur J Nucl Med"},{"key":"10.1097\/JTO.0000000000000051_bib21","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.lungcan.2003.11.008","article-title":"Comparison of whole-body FDG-PET to bone scan for detection of bone metastases in patients with a new diagnosis of lung cancer","volume":"44","author":"Cheran","year":"2004","journal-title":"Lung Cancer"},{"key":"10.1097\/JTO.0000000000000051_bib22","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.lungcan.2012.05.094","article-title":"Prognostic factors for non-small cell lung cancer with bone metastasis at the time of diagnosis","volume":"77","author":"Bae","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1097\/JTO.0000000000000051_bib23","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/bjc.1988.194","article-title":"Biochemical prediction of response of bone metastases to treatment","volume":"58","author":"Coleman","year":"1988","journal-title":"Br J Cancer"},{"issue":"8 Pt 1","key":"10.1097\/JTO.0000000000000051_bib24","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1093\/clinchem\/45.8.1240","article-title":"Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases","volume":"45","author":"Berruti","year":"1999","journal-title":"Clin Chem"},{"key":"10.1097\/JTO.0000000000000051_bib25","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1200\/JCO.1986.4.5.702","article-title":"Long-term survivors in metastatic non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study","volume":"4","author":"Finkelstein","year":"1986","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0000000000000051_bib26","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1200\/JCO.2005.04.177","article-title":"Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on eastern cooperative oncology group data","volume":"23","author":"Hoang","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0000000000000051_bib27","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/JTO.0b013e31816de2b8","volume":"3","author":"Sculier","year":"2008","journal-title":"J Thorac Oncol"},{"key":"10.1097\/JTO.0000000000000051_bib28","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1038\/sj.bjc.6601437","article-title":"Bone resorption predicts for skeletal complications in metastatic bone disease","volume":"89","author":"Brown","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1097\/JTO.0000000000000051_bib29","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/jnci\/dji002","article-title":"Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors","volume":"97","author":"Brown","year":"2005","journal-title":"J Natl Cancer Inst"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086415301945?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086415301945?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T04:09:45Z","timestamp":1597378185000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086415301945"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["S1556086415301945"],"URL":"https:\/\/doi.org\/10.1097\/jto.0000000000000051","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]}}}